|
1
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singhal N, Vatandoust S and Brown MP:
Phase II study evaluating efficacy and safety of everolimus with
letrozole for management of advanced (unresectable or metastatic)
non-small cell lung cancer after failure of platinum-based
treatment: A preliminary analysis of toxicity. Cancer Chemother
Pharmacol. 75:325–331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Langer CJ, Novello S, Park K, Krzakowski
M, Karp DD, Mok T, Benner RJ, Scranton JR, Olszanski AJ and Jassem
J: Randomized, phase III trial of first-line figitumumab in
combination with paclitaxel and carboplatin versus paclitaxel and
carboplatin alone in patients with advanced non-small-cell lung
cancer. J Clin Oncol. 32:2059–2066. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heigener DF, Pereira JR, Felip E, Mazal J,
Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R and Gatzemeier U:
Weekly and every 2 weeks cetuximab maintenance therapy after
platinum-based chemotherapy plus cetuximab as first-line treatment
for non-small cell lung cancer: Randomized non-comparative phase
IIIb NEXT trial. Target Oncol. 10:255–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pu Q, Huang Y, Lu Y, Peng Y, Zhang J, Feng
G, Wang C, Liu L and Dai Y: Tissue-specific and plasma microRNA
profiles could be promising biomarkers of histological
classification and TNM stage in non-small cell lung cancer. Thorac
Cancer. 7:348–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pastorkova Z, Skarda J and Andel J: The
role of microRNA in metastatic processes of non-small cell lung
carcinoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
160:343–357. 2016.PubMed/NCBI
|
|
7
|
Wang G, Wang R, Strulovici-Barel Y, Salit
J, Staudt MR, Ahmed J, Tilley AE, Yee-Levin J, Hollmann C, Harvey
BG, et al: Persistence of smoking-induced dysregulation of miRNA
expression in the small airway epithelium despite smoking
cessation. PLoS One. 10:e01208242015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bianchi F, Nicassio F, Marzi M, Belloni E,
Dall'olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G and Di
Fiore PP: A serum circulating miRNA diagnostic test to identify
asymptomatic high-risk individuals with early stage lung cancer.
EMBO Mol Med. 3:495–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee JH, Voortman J, Dingemans AM, Voeller
DM, Pham T, Wang Y and Giaccone G: MicroRNA expression and clinical
outcome of small cell lung cancer. PLoS One. 6:e213002011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kumarswamy R, Mudduluru G, Ceppi P,
Muppala S, Kozlowski M, Niklinski J, Papotti M and Allgayer H:
MicroRNA-30a inhibits epithelial-to-mesenchymal transition by
targeting Snai1 and is downregulated in non-small cell lung cancer.
Int J Cancer. 130:2044–2053. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tibaldi C, D'Incecco A and Lagana A:
MicroRNAs and Targeted Therapies in Non-small Cell Lung Cancer:
Minireview. Anticancer Agents Med Chem. 15:694–700. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma R, Wang C, Wang J, Wang D and Xu J:
miRNA-mRNA interaction network in non-small-cell lung cancer.
Interdiscip Sci. 209–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao X, Liu M and Li D: Oleanolic acid
suppresses the proliferation of lung carcinoma cells by
miR-122/Cyclin G1/MEF2D axis. Mol Cell Biochem. 400:1–7. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X,
Bai X, Sun Y, Zhang X, Sun H, et al: miR-218 suppressed the growth
of lung carcinoma by reducing MEF2D expression. Tumour Biol.
37:2891–2900. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang R, Zhang Y and Li H:
miR-1244/myocyte enhancer factor 2D regulatory loop contributes to
the growth of lung carcinoma. DNA Cell Biol. 34:692–700. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yao L, Xu S, Xu J, Yang C, Wang J and Sun
D: S-1 plus cisplatin with concurrent radiotherapy versus cisplatin
alone with concurrent radiotherapy for stage III non-small cell
lung cancer: A pilot randomized controlled trial. Radiat Oncol.
10:102015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hattori Y, Satouchi M, Shimada T, Urata Y,
Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, et
al: A phase 2 study of bevacizumab in combination with carboplatin
and paclitaxel in patients with non-squamous non-small-cell lung
cancer harboring mutations of epidermal growth factor receptor
(EGFR) after failing first-line EGFR-tyrosine kinase inhibitors
(HANSHIN Oncology Group 0109). Lung Cancer. 87:136–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mariano C, Bosdet I, Karsan A, Ionescu D,
Murray N, Laskin JJ, Zhai Y, Melosky B, Sun S and Ho C: A
population-based review of the feasibility of platinum-based
combination chemotherapy after tyrosine kinase inhibition in EGFR
mutation positive non-small cell lung cancer patients with advanced
disease. Lung Cancer. 83:73–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rothschild SI: Epigenetic Therapy in Lung
Cancer - Role of microRNAs. Front Oncol. 3:1582013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buitrago DH, Patnaik SK, Kadota K,
Kannisto E, Jones DR and Adusumilli PS: Small RNA sequencing for
profiling microRNAs in long-term preserved formalin-fixed and
paraffin-embedded non-small cell lung cancer tumor specimens. PLoS
One. 10:e01215212015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim MK, Kim SC, Kang JI, Hyun JH, Boo HJ,
Eun SY, Park DB, Yoo ES, Kang HK and Kang JH:
6-Hydroxydopamine-induced PC12 cell death is mediated by MEF2D
down-regulation. Neurochem Res. 36:223–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiao WL, Hu HY, Shi BW, Zang LJ, Jin W and
Lin Q: Lentivirus-mediated knockdown of TSP50 suppresses the growth
of non-small cell lung cancer cells via G0/G1 phase arrest. Oncol
Rep. 35:3409–3418. 2016.PubMed/NCBI
|
|
23
|
Zhang XS, Zhao C, Tang WZ, Wu XJ and Zhao
YQ: Gypensapogenin H, a novel dammarane-type triterpene induces
cell cycle arrest and apoptosis on prostate cancer cells. Steroids.
104:276–283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu J, Chen M, Chen N, Ma A, Zhu C, Zhao
R, Jiang M, Zhou J, Ye L, Fu H, et al: Glycyrrhetinic acid induces
G1-phase cell cycle arrest in human non-small cell lung cancer
cells through endoplasmic reticulum stress pathway. Int J Oncol.
46:981–988. 2015.PubMed/NCBI
|
|
25
|
Liao K, Li J and Wang Z:
Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclin
D1 pathway and induces apoptosis in A549 lung cancer cells. Int J
Clin Exp Pathol. 7:8684–8691. 2014.PubMed/NCBI
|
|
26
|
Li Q, Dong Q and Wang E: Rsf-1 is
overexpressed in non-small cell lung cancers and regulates cyclin
D1 expression and ERK activity. Biochem Biophys Res Commun.
420:6–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Recchia AG, Musti AM, Lanzino M, Panno ML,
Turano E, Zumpano R, Belfiore A, Andò S and Maggiolini M: A
cross-talk between the androgen receptor and the epidermal growth
factor receptor leads to p38MAPK-dependent activation of mTOR and
cyclin D1 expression in prostate and lung cancer cells. Int J
Biochem Cell Biol. 41:603–614. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lingfei K, Pingzhang Y, Zhengguo L,
Jianhua G and Yaowu Z: A study on p16, pRb, cdk4 and cyclin D1
expression in non-small cell lung cancers. Cancer Lett. 130:93–101.
1998. View Article : Google Scholar : PubMed/NCBI
|
